Sweden's doctors see promise in obesity drugs but worry about cost and confusion
Swedish primary care physicians view new anti-obesity medications as useful tools for weight loss, but cite major barriers to wider adoption: unclear treatment timelines, conflicting clinical guidance, and financial constraints. The findings suggest healthcare systems need clearer protocols and pricing strategies to unlock the potential of these increasingly important drugs.
Originaltitel: Experiences and perceptions of pharmacological treatment of obesity among primary health care physicians in Sweden: a qualitative content analysis study.
Svenska primärvårdsläkare ser nya fetmaläkemedel som värdefulla för att initiera behandling och stödja viktminskning, men möter betydande hinder i kliniken. En kvalitativ studie vid Lunds universitet intervjuade elva läkare i Skåne och identifierade fyra kritiska utmaningar: osäkerhet kring fetmas klassificering, avsaknad av eniga behandlingsriktlinjer, oklar behandlingsvaraktighet och ekonomiska barriärer. Läkarna beskrev också otillräcklig kunskap om läkemedlens långtidseffekter och patienters adherens. Studien indikerar att nationella behandlingsprotokoll och tydligare rekommendationer skulle minska osäkerheten bland primärvårdsproviders och möjliggöra mer konsekvent användning av antiobesitasmediciner. För inköpschefer och regionala beslutsfattare framgår att investeringar i riktlinjer och läkarutbildning föregår massiv implementering. Ytterligare forskning i andra svenska regioner behövs för att informera policy.
BACKGROUND: High body mass index (BMI) accounts for approximately 7% of total mortality in Sweden and represents a major global public health challenge. In recent years, new anti-obesity medications (AOMs) have been introduced; however, knowledge about how primary care physicians (PCPs) perceive these medications in clinical practice is limited. Understanding PCPs' perspectives is essential as these medications are expected to play an increasingly important role in obesity care. AIM: To explore PCPs' experiences and perceptions of AOMs, and to identify perceived challenges and opportunities related to their clinical use. METHODS: A qualitative study was conducted, including 11 in-depth interviews with PCPs working in regional and private primary health care centers in Skåne, Sweden. Data were analyzed using qualitative content analysis. RESULTS: The analysis yielded one overarching theme: CONCLUSIONS: Pharmacological treatment of obesity was perceived as useful for initiating discussions and supporting weight loss. However, PCPs reported challenges related to obesity complexity, lack of consensus on classification and treatment, unclear treatment duration, and economic barriers. Clear guidelines and shared understanding of obesity treatment may reduce uncertainty and provide stronger support for PCPs. Further research incorporating patient perspectives and other Swedish regions can inform national guidelines and enhance the overall understanding of AOMs.